Sysmex (OTCMKTS:SSMXY) Shares Gap Down – Should You Sell?

Sysmex Corporation ADR (OTCMKTS:SSMXY) gapped down before the market opened on Monday . The stock had previously closed at $11.84, but opened at $11.18. Sysmex shares last traded at $11.61, with a volume of 880 shares.

Analyst Upgrades and Downgrades

Separately, Zacks Research cut shares of Sysmex from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 14th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold”.

Sysmex Stock Performance

The stock’s 50-day simple moving average is $9.69 and its 200-day simple moving average is $9.16. The company has a current ratio of 3.26, a quick ratio of 2.46 and a debt-to-equity ratio of 0.12. The stock has a market cap of $7.30 billion, a price-to-earnings ratio of 27.62 and a beta of 1.05.

Sysmex (OTCMKTS:SSMXY) last issued its earnings results on Friday, August 7th. The company reported $0.09 EPS for the quarter, beating the consensus estimate of $0.07 by $0.02. Sysmex had a net margin of 7.62% and a return on equity of 7.87%. The company had revenue of $825.85 million during the quarter, compared to analysts’ expectations of $741.67 million. Sysmex has set its FY 2026 guidance at 0.382-0.382 EPS. Analysts forecast that Sysmex Corporation ADR will post 0.38 earnings per share for the current fiscal year.

Sysmex Company Profile

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.